The aim is to evaluate the efficacy of restoring apoptosis in tumor cells, using the first-in-class humanized monoclonal antibody that blocks Netrin-1 (NP137) alone or combined with an anti-PD-1 [99]. The gene discussed is NTN1; the disease is neoplasm.